Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma

Overview

BRAF V600-mutant metastatic melanoma are commonly treated using a combination of anti-BRAF and anti-MEK tyrosine kinase inhibitors (TKIs). The OPTIMEL trial aims to study the interest of therapeutic drug monitoring (TDM) of TKIs and circulating tumor DNA (ctDNA) detected in plasma of patients with metastatic melanoma for disease monitoring. 35 patients with metastatic melanoma and treated with dabrafenib and trametinib will be enrolled in this trial. Blood samples will be collected for the determination of TKIs concentration and ctDNA detection.

Full Title of Study: “Therapeutic Drug Monitoring of Kinase Inhibitors and Study of Circulating Tumor DNA in Patients With Mutated BRAF Metastatic Cutaneous Melanoma and Treated With Anti-BRAF and Anti-MEK Kinase Inhibitors”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 17, 2022

Interventions

  • Other: Blood sampling
    • 2×10 ml of patient peripherical blood will be collected at D0, D15, D30, D90, D180, D270 and with progression or at the end of the follow-up at the 12th month.

Arms, Groups and Cohorts

  • Experimental: Biological

Clinical Trial Outcome Measures

Primary Measures

  • Link between the presence of circulating tumor DNA and plasma concentrations of kinase inhibitors n patient with advanced BRAF(V600) mutated melanoma
    • Time Frame: 1 day
    • ctDNA in patient with advanced BRAF(V600) mutated melanoma is estimated by the ratio of the Ct of the sample to the control. Plasma concentrations of anti-BRAF and anti-MEK tyrosine kinase inhibitors are expressed in μg / mL

Participating in This Clinical Trial

Inclusion Criteria

  • Men and women 18 years of age and older – Histologic proven advanced skin melanoma (Stage IV or stage IIIc inoperable) with BRAF V600 mutation – Patient who will treated with combined kinase inhibitors (dabrafenib + trametinib). – Patient able to stand a blood collection of 20 mL – Ability to provide an informed written consent form – Patient must be affiliated to a social security system – Patient's legal capacity to consent to study participation and to understand and comply with the requirements of the study. Exclusion Criteria:

  • Patient with mucosal melanoma – Patient with non-metastatic skin melanoma (All stages except stage IV and stage III C inoperable) – Patient with another synchronous cancer, or within 3 years – Patient with a contraindication to blood collection of 20 mL – Patient deprived of liberty or under supervision – Patient unable to receive kinase inhibitor therapy – Patient treated with another combined kinase inhibitors than dabrafenib and trametinib – Pregnant or breastfeeding women – Patient (man or woman) of childbearing age who does not agree to use of contraceptive methods validated during the study

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Institut de Cancérologie de Lorraine
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Geoffrois Lionnel, MD, Principal Investigator, Institut de Cancérologie de Lorraine

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.